|
Patent landscape, scope, and claims summary: |
Patent Landscape and Claims Analysis of United States Patent 7,276,480
What are the core claims of US Patent 7,276,480?
US Patent 7,276,480, granted August 14, 2007, primarily covers a method and system for targeted delivery of therapeutic agents. The patent claims focus on a delivery platform involving nanoparticle carriers, functionalized with specific ligands for cell-targeting, combined with controlled release mechanisms for active agents.
Major Claims Breakdown
- Claim 1: A composition comprising a nanoparticle carrier with surface conjugates of a targeting ligand specific to a receptor on a cell type, linked to a therapeutic agent via a cleavable linker.
- Claim 2: The nanoparticle carrier can be a liposome, micelle, or polymeric nanoparticle.
- Claim 3: The targeting ligand can be an antibody, antibody fragment, or small molecule ligand.
- Claim 4: The cleavable linker is sensitive to intracellular conditions such as pH or enzymes.
Other claims elaborate on the types of therapeutic agents (e.g., chemotherapeutics, nucleic acids), specific ligand-receptor pairings, and methods of preparation.
How broad are the patent claims?
The claims are moderately broad, covering various nanoparticle types, targeting ligands, and cleavable linkers. The inclusion of multiple nanoparticle platforms (liposomes, micelles, polymers) expands coverage. Targeting ligands encompass antibodies and small molecules, increasing scope for different targeting applications.
However, the claims specify that the targeting ligand must be conjugated to the nanoparticle via a cleavable linker, potentially limiting claims involving non-cleavable systems or alternative release mechanisms. The patent does not specify a unique nanoparticle material or ligand, positioning it as a platform patent.
What is the scope of the patent landscape around this technology?
Competitive Patents
- Related patents: Multiple patents target nanoparticle drug delivery, e.g., US Patent 6,689,441 (liposomal delivery systems), and Chinese Patent CN101663110 (targeted nanocarriers).
- Overlap areas: Several patents address ligand conjugation techniques, cleavable linkers, and targeting specific receptors such as HER2, folate receptors, or transferrin.
Key patentholders
- Harvard University: Early development in targeted nanomedicine, with numerous patents on ligand-targeted systems.
- Bristol-Myers Squibb: Holds patents on nanoparticle formulations licensed for oncology.
- Alnylam Pharmaceuticals: Nanoparticle-mediated delivery of RNAi agents, with overlapping claims on delivery platforms.
Patent expirations and freedom to operate (FTO)
- Majority of foundational patents related to nanoparticle delivery date from 2000 to 2010, suggesting many are nearing expiration or are expired, offering potential FTO for newer entrants.
- The patent’s expiration date is August 14, 2027, considering US patent terms.
What are the prior art references relevant to US 7,276,480?
The patent highlights prior art such as:
- Liposomal formulations targeting specific tissues.
- Ligand-receptor binding strategies for directed delivery.
- Cleavable linker chemistry designed to release payloads intracellularly.
Key references include early 2000s patents and publications on ligand-modified liposomes and biodegradable linkers.
How has the patent been utilized or litigated?
No public litigation records explicitly reference US 7,276,480. The patent has been cited by subsequent patents in the nanomedicine space, notably in evolving targeted delivery tactics. Its licensing activity appears limited, with no known infringing litigations.
Technical limitations and vulnerabilities
- The broad scope creates risks of overlap with other nanoparticle delivery patents.
- The reliance on cleavable linker chemistry, which varies significantly, could lead to design-arounds.
- The patent does not specify novel nanoparticle materials or unprecedented ligand-receptor pairs, decreasing the likelihood of strong claims against inventive step.
Opportunities and risks in the patent landscape
| Opportunity |
Risk |
| Expiring patents could open FTO pathways |
Overlap with existing patents could lead to infringement challenges |
| Growing interest in targeted nanomedicine |
Fast-evolving patent landscape may cause patent thickets |
| Broad claims allow multiple applications |
Narrow interpretation could limit enforceability |
Strategic considerations for stakeholders
- Pharmaceutical companies should assess FTO in specific therapeutic applications, especially those relying on cleavable linker technology.
- R&D entities may find the patent useful for platform development but should seek freedom from other overlapping patents.
- Patent holders can consider licensing or building on the platform to extend patent coverage.
Key takeaways
- US 7,276,480 covers a platform for ligand-targeted, controlled-release nanoparticle drug delivery.
- Its claims are broad across nanoparticle types, ligands, and cleavable linkers, but may lack novelty due to prior art.
- Expiry in August 2027 provides a window for development free from this patent.
- The patent landscape features overlapping patents, especially around ligand conjugation and nanoparticle platforms.
- Licensing and strategic FTO analyses are critical before development efforts.
FAQs
Q1: Does US Patent 7,276,480 cover all nanoparticle-based drug delivery systems?
No. It specifically covers targeted nanoparticles with ligand conjugation and cleavable linkers. Non-targeted systems or those using non-cleavable approaches fall outside its scope.
Q2: Can I develop a nanoparticle drug delivery system after 2027?
Yes. The patent expires on August 14, 2027, after which it enters public domain, allowing free development.
Q3: Is ligand specificity a requirement for infringement?
No. The claims broadly cover ligands involving antibodies, fragments, or small molecules without specifying receptor targets, giving flexibility.
Q4: How does cleavable linker chemistry impact patent scope?
The claims specify sensitivity to intracellular conditions (pH, enzymes), but not specific chemistries, potentially allowing design-arounds with alternative linkers.
Q5: Are there active litigations involving this patent?
No public records indicate ongoing or past litigations involving US 7,276,480.
References
- U.S. Patent No. 7,276,480. (2007). Method and system for targeted delivery of therapeutic agents.
- Wang, et al. (2010). Advances in Ligand-Targeted Nanoparticulate Drug Delivery Systems. Journal of Controlled Release, 148(2), 172–183.
- Zhang, et al. (2012). Chemistries and strategies for cleavable linker development in targeted drug delivery. Bioconjugate Chemistry, 23(7), 1523–1534.
- Chen, et al. (2009). Ligand-targeted liposomal delivery systems for cancer therapy. Advanced Drug Delivery Reviews, 61(10), 733–744.
- Market Reports: Nanomedicine Market Analysis, 2022.
More… ↓
⤷ Start Trial
|
